Overall, our network meta-analysis found that ARBs as a class were not associated with an increased risk of cardiovascular risk (major cardiovascular outcome, cardiovascular death, myocardial infarction, stroke, angina pectoris, or hospitalization for heart failure) when compared with ACE inhibitors or placebo. The gene discussed is ACE; the disease is myocardial infarction.